Gunnedah Diagnostic Imaging 99 BARBER ST

GUNNEDAH

Phone: 0267427722 Fax: 0267422051

DATE:

ACTION - call patient within file report

no action

<u>Datient se</u>en etre:

Dr Okwun Ojah

NARRABRI

4/159 MAITLAND STREET

Patient:

ALISHA STANFORD Drs Signature:

176 TUPPIARI ROAD

JACKS CREEK

NSW

Reference: 1474235

Date of Birth: 07/01/1989

- Einde W. Land

Referred by: Dr Okwun Ojah

Visit Date: 20 Jun 2019

ULTRASOUND ABDOMINAL WALL

Clinical History:

Had caesarean 31/5/2019. There could be retained products. Pain left abdominal flank. Pain on urination.

Findings:

Transabdominal scanning.

The uterus is anteverted. Throughout the endometrial cavity there is markedly heterogeneous echotexture over approximate span of 9.4 x 3.4 x 5.0cm. This is non-vascular. Cervical canal appears open.

The ovarian volumes are 4ml on the right and 5ml on the left. No adnexal mass.

Throughout the caesarean scar site, there is no focal findings such as fluid collection.

COMMENT:

Markedly heterogeneous complex appearing material filling the endometrial cavity suggesting blood clots or non-vascular products of conception.

DR ALLEN KO TMI RAD

Text Verified by: DR ALLEN KO

(This report and images are available online at https://pacs.alpenglow.com.au/InteleConnect)

ALISHA STANFORD US ABDO WALL 20 Jun 2019

The information contained in this facsimile message is legally privileged and confidential, intended only for the use of the individual named above. If the receiver is not the intended recipient the receiver is hereby notified that any use, dissemination, distribution, publication or copying of this facsimile is prohibited. If you have received this facsimile in error please notify the practice immediately and arrangements will be unade to retrieve or destroy it.

PI WIII Speak with DI Appen about this

Patient Address: 176 TUPPIARI RD, NARRABRI 2390

D.O.B: 7/01/1989 Medicare No.: 2612631437 Lab. Reference: 22-18152406-VBF-0

Addressee: DR MICHAEL LING Provider: Laverty Pathology

Referred by: DR. MICHAEL LING

Gender: F

IHI No.:

Date Requested: 25/08/2022 Date Collected: 25/08/2022 Date Complete: Final

Specimen:

Subject(Test Name): B12, FOLATE, R.C.FOLATE (VBF-0)

Clinical Information:

Clinical Notes : on Oroxine + lethargy.

VITAMIN B12 AND FOLATE STUDIES

Vitamin B12	274	pmol/L	(301-740)
Active B12	124	pmol/L	(> 40)
Serum Folate	31.5	nmol/L	(> 9.0)

Serum Vitamin B12 Assay:

DEFICIENCY	BORDERLINE	SUFFICIENCY	
<150 pmol/L	150 - 300 pmol/L	>300 - 740 pmol/L	

For patients with total B12 levels in the low or borderline range, testing for active B12 (holotranscobalamin II) will automatically be performed to resolve B12 status. Active B12 is the biologically active fraction of total serum B12, and a superior indicator of B12 status. Up to 15% of individuals may have a deficiency of the carrier protein haptocorrin, which does not result in clinical B12 deficiency, despite low total B12 levels.

Serum Active B12 Assay:

This active B12 result indicates that the patient is likely to be vitamin B12 sufficient. Patients with renal impairment may still be B12 depleted despite an active B12 level within this range. For these patients, correlation with total B12, homocysteine and/or methylmalonate is required.

Folate Interpretation:

1		1	DEFICIENCY	BORDERLINE		SUFFICIENCY		
j	Serum Folate:	 +-	<4.5 nmol/L		4.5 - 9.0 nmol/L	>9.0 nmol/L		
i	RBC Folate:		<340 nmol/L		340 - 570 nmol/L	>570 nmol/L		

Serum Folate Assay:

In the absence of recent oral intake, a serum folate $>9.0~\mathrm{nmol/L}$ effectively rules out folate deficiency.

Please note that Medicare requirements for folate testing reflect current best practice. Red cell folate will be reserved for patients with borderline values for serum folate (between 4.5 and 9.0 nmol/L.)

Please note that as of 03/05/2022, Laverty Pathology changed to the Atellica analyser for Active B12 testing. Results may be slightly higher

* compared to the previous method. Reference intervals have been adjusted accordingly. If further information is required, please contact a Chemical Pathologist on 9005 7000.

Requested Tests : VBF, TFT, HOR, FE, FBE

Patient Address: 176 TUPPIARI RD, NARRABRI 2390

D.O.B: 7/01/1989

Medicare No.: 2612631437 **Lab. Reference:** 22-18152406-TFT-0

Provider: Laverty Pathology Addressee: DR MICHAEL LING Referred by: DR. MICHAEL LING

Gender: F

25/08/2022

1

Final

IHI No.:

Date Requested: 25/08/2022 Date Collected:

25/08/2022

Date Performed: Complete:

Specimen:

Subject(Test Name): THYROID FUNCTION TEST (TFT-0)

Clinical Information:

Clinical Notes : on Oroxine + lethargy.

THYROID PROFILE

Specimen Type: Serum

TSH 2.0 mIU/L (0.5-4.0)FT4 18 pmol/L (10-20)FT3 5.4 pmol/L (3.5-6.0)

Result(s) consistent with euthyroidism.

Please note the above reference intervals have been developed from a non-pregnant healthy general population study.

Requested Tests : VBF*, TFT, HOR, FE, FBE

Patient Address: 176 TUPPIARI RD, NARRABRI 2390

D.O.B: 7/01/1989

Medicare No.: Gender: F 2612631437 Lab. Reference: IHI No.: 22-18152406-HOR-0

Addressee: DR MICHAEL LING Provider: Laverty Pathology Referred by: DR. MICHAEL LING

Date Requested: 25/08/2022 Date Collected:

Date Performed: 25/08/2022 25/08/2022 Complete: Final

Specimen:

Subject(Test Name): HORMONE PROFILE (HOR-0)

Clinical Information:

Clinical Notes : on Oroxine + lethargy.

SERUM HORMONE PROFILE Specimen Type: Serum Request Date FSH LH PROG E2 (ATEL) E2 (BECK) LH/FSH Number Collected IU/L IU/L nmol/L pmol/L pmol/L 18152406 25 Aug 22 Ratio Reference Ranges FSH T.H PROG OESTRADIOL Follicular 2-12 2-12 0.5 - 4.5100-530 12-30 Midcycle >15 235-1300 Luteal 2-12 2-15 10.6-89.1 205-790 Menopausal >25 >10 <100 Prepubertal <6 <4

PLEASE NOTE:

'E2 (ATEL)' - Oestradiol by Siemens Atellica assay 'E2 (BECK)' - Oestradiol by Beckman Access assay

Requested Tests : VBF^* , TFT, HOR, FE, FBE

Patient Address: 176 TUPPIARI RD, NARRABRI 2390

D.O.B: 7/01/1989 Medicare No.: 2612631437

Lab. Reference: 22-18152406-FE-0 **Provider:** Laverty Pathology Addressee: DR MICHAEL LING Referred by: DR. MICHAEL LING

Gender: F

Date Performed: 25/08/2022

Complete: Final

IHI No.:

Date Requested: 25/08/2022 **Date Collected:** 25/08/2022

Specimen:

Subject(Test Name): IRON STUDIES (FE-0)

Clinical Information:

Clinical Notes : on Oroxine + lethargy.

IRON STUDIES

Specimen Type: Serum Serum Iron umol/L (10-30)Transferrin umol/L 32 (32 - 48)Transferrin Saturation 22 용 (13-45)Serum Ferritin ug/L 36 (30-165)

Normal iron studies.

Requested Tests : VBF*, TFT*, HOR*, FE, FBE

Patient Address: 176 TUPPIARI RD, NARRABRI 2390

D.O.B: 7/01/1989 Gender: F Medicare No.: 2612631437 IHI No.:

Lab. Reference: 22-18152406-FBE-0 Provider: Laverty Pathology
Addressee: DR MICHAEL LING Referred by: DR. MICHAEL LING

Date Requested: 25/08/2022 **Date Collected:** 25/08/2022

Date Performed: 25/08/2022 Complete: Final

Specimen:

Subject(Test Name): HAEMATOLOGY (FBE-0)

Clinical Information:

Clinical Notes : on Oroxine + lethargy.

Date Collected 25 Aug 22
Time Collected 09:35

Specimen Type: EDTA

142 g/L (115-165) 4.8 x10^12 /L (3.9-5.8) WBC 6.6 x10^9 /L (4.0-11.0) Neut 4.2 x10^9 /L (4.0-11.0) Lymp 1.8 x10^9 /L (2.0-7.5) Lymp 1.8 x10^9 /L (1.0-4.0) Mono 0.5 x10^9 /L (0.2-1.0) Eos 0.1 x10^9 /L (< 0.7) Baso 0.1 x10^9 /L (< 0.2) RCC 0.42 (0.34 - 0.47)Hct MCV 87 fL (79 - 99)MCH 30 pg (27 - 34)MCHC 340 g/L RDW 12.7 % (320 - 360)(10.0-17.0)Plat 227 x10^9 /L (150-400)

HAEMATOLOGY: FBC parameters are within reference range.

Requested Tests : VBF*, TFT*, HOR*, FE*, FBE